References
- Trussell J. Contraceptive efficacy. In: Hatcher RA, Trussell J, Nelson AL, Cates W, Kowal D, Policar M, editors. Contraceptive technology: twentieth revised edition. New York (NY): Ardent Media; 2011.
- Mansour D, Inki P, Gemzell-Danielsson K. Efficacy of contraceptive methods: a review of the literature. Eur J of Contraception Reprod Heal Care. 2010;15(1):4–16.
- Christin-Maitre S. History of oral contraceptive drugs and their use worldwide. Best Pract Res Clin Endocrinol Metab. 2013;27:3–12.
- Naess IA, Christiansen SC, Romundstad P, et al. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost. 2007;5:692–699.
- Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):3–14.
- European Medicines Agency. Benefits of combined hormonal contraceptives (CHCs) continue to outweigh risks – CHMP endorses PRAC recommendation. [cited 2020 Oct 14]. https://www.ema.europa.eu/en/news/benefits-combined-hormonal-contraceptives-chcs-continue-outweigh-risks-chmp-endorses-prac
- European Medicines Agency. Assessment report for combined hormonal contraceptives containing medicinal products, 2014.
- Roach REJ, Helmerhorst FM, Lijfering WM, et al. Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke. Cochrane Database Syst Rev. 2015;2015(8):CD011054.
- Tepper NK, Whiteman MK, Marchbanks PA, James AH, et al. Progestin-only contraception and thromboembolism: a systematic review. Contraception. 2016;94(6):678–700.
- American Academy of Family Physicians. Contraception choices in women with underlying medical conditions. Am Fam Physician. 2010;82:621–628.
- Estonian Health Insurance Fund. Annual reports. [cited 2020 Sep 28]. https://www.haigekassa.ee/en/organisation/annual-reports-0
- WHO Collaborating Centre for Drug Statistics Methodology. [cited 2020 Jun 2]. https://www.whocc.no/
- Hognert H, Skjeldestad FE, Gemzell-Danielsson K, et al. Ecological study on the use of hormonal contraception, abortions and births among teenagers in the Nordic countries. BMJ Open. BMJ Publishing Group. 2018;8(10):e022473.
- Health Products Regulatory Authority. Depo-Provera 150 mg/ml Suspension for injection. Summary of product characteristics. [cited 2020 Jun 2].
- Eesti Statistikaamet. Statistika andmebaas. RV021: Rahvastik soo ja vanuserühma järgi, 1. jaanuar. [cited 2020 Jun 1]. http://andmebaas.stat.ee/Index.aspx?lang=et&SubSessionId=219a1572-7f49-449f-af6b-bc5274b3c8b7&themetreeid=5
- Estonian Agency of Medicines. Register of medicinal products. checklist for prescribers. [cited 2020 Dec 28]. https://www.ravimiregister.ee/Data//aRMM/14780/1897820d-121e-4633-bacd-7a65ae7f0f1f/Tervishoiutöötajale_Kontroll-loend.pdf
- Health Products Regulatory Authority. Find a medicine. Checklist for prescribers. [cited 2020 Dec 28]. http://www.hpra.ie/img/uploaded/swedocuments/03526291-c9d1-401f-ba06-2aa94b491e67.pdf
- RStudio Team 2020. RStudio: integrated Development for R. [Internet]. RStudio, PBC, Boston, MA. https://www.rstudio.com/
- United Nations, Department of Economic and Social Affairs, Population Division. 2019. Contraceptive Use by Method 2019: Data Booklet (ST/ESA/SER.A/435).
- Hognert H, Skjeldestad FE, Gemzell-Danielsson K, et al. High birth rates despite easy access to contraception and abortion: a cross-sectional study. Acta Obstet Gynecol Scand. 2017;96(12):1414–1422.
- National Institute for Health Development. Health Statistics and Health Research Database. [cited 2020 Oct 21]. https://statistika.tai.ee/pxweb/en/Andmebaas/Andmebaas__01Rahvastik__03Abordid/RK20.px/table/tableViewLayout2/
- Sedgh G, Singh S, Hussain R. Intended and unintended pregnancies Worldwide in 2012 and recent trends. Stud Fam Plann. 2014;45:301–314.
- Shoupe D. LARC methods: entering a new age of contraception and reproductive health. Contracept Reprod Med. 2016;1:4.
- Estonian State Agency of medicines. Statistics on medicines. [cited 2020 Oct 20]. https://www.ravimiamet.ee/en/statistics-medicines
- Ekman J, Skjeldestad FE. Do Norwegian providers comply with national recommendations when prescribing combined oral contraceptives to starters? A cohort study. BMJ Open. BMJ Publishing Group. 2019;9(11):e027888.
- de Bastos M, Stegeman BH, Rosendaal FR, et al. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst. Rev. 2014(3):CD010813.
- Food and Drug Administration. Combined hormonal contraceptives (CHCs) and the risk of cardiovascular disease endpoints (CHC-CVD final report 111022v2); 2011. [cited 2020 Oct 23]. https://www.fda.gov/media/82335/download.
- Lidegaard Ø, Nielsen LH, Skovlund CW, et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study. BMJ. 2011;343:2001–2009.
- Plu-Bureau G, Maitrot-Mantelet L, Hugon-Rodin J, et al. Hormonal contraceptives and venous thromboembolism: an epidemiological update. Best Pract Res Clin Endocrinol Metab Bailliere Tindall Ltd. 2013;27(1):25–34.
- Lauring JR, Lehman EB, Deimling TA, et al. Combined hormonal contraception use in reproductive-age women with contraindications to estrogen use. Am J Obstet Gynecol. 2016;215:330.e1-330–e7.
- Dhont M. History of oral contraception. Eur J Contracept Reprod Heal Care. 2010;15(sup2):S12–S8.
- Nicholson M, Chan N, Bhagirath V, et al. Prevention of Venous Thromboembolism in 2020 and Beyond. JCM. 2020;9(8):2467.
- Lidegaard Ø, Løkkegaard E, Jensen A, et al. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med. 2012;366:2257–2266.
- Lidegaard O, Nielsen LH, Skovlund CW, et al. Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10. BMJ. 2012;344:e2990.
- Van Hylckama Vlieg A, Helmerhorst FM, Rosendaal FR. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device. Arterioscler Thromb Vasc Biol. 2010;30:2297–2300.